β-arrestin protects neurons by mediating endogenous opioid arrest of inflammatory microglia

Cell Death and Differentiation

Volumn 21, Issue 3, 2014, Pages 397-406

  Feng, X ^a   Wu, C Y ^a   Burton, F H ^a   Loh, H H ^a   Wei, L N ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

arrestin; dynorphin; kappa opioid receptor; microglial inflammation; neurotoxicity

Indexed keywords

BETA ARRESTIN; CYTOKINE; DYNORPHIN; KAPPA OPIATE RECEPTOR; MAP KINASE KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; OPIATE PEPTIDE; RETINA S ANTIGEN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TAB1 PROTEIN, MOUSE;

AGONISTS; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL DEATH; FEMALE; INFLAMMATION; MALE; METABOLISM; MICROGLIA; MOUSE; NERVE CELL; PARKINSON DISEASE; PATHOLOGY; PHYSIOLOGY; PREGNANCY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ARRESTINS; CELL DEATH; CYTOKINES; DYNORPHINS; FEMALE; INFLAMMATION; MALE; MAP KINASE KINASE KINASES; MICE; MICE, INBRED C57BL; MICROGLIA; NEURONS; OPIOID PEPTIDES; PARKINSON DISEASE; PREGNANCY; RECEPTORS, OPIOID, KAPPA;

EID: 84893859327     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2013.152     Document Type: Article

References (53)

1. Imamura K, Hishikawa N, Sawada M, Nagatsu T, Yoshida M, Hashizume Y. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol 2003; 106: 518-526
2. Kim W-G, Mohney RP, Wilson B, Jeohn GH, Liu B, Hong JS. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: Role of microglia. J Neurosci 2000; 20: 6309-6316
3. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinsons and Alzheimer's disease brains. Neurology 1988; 38: 1285-1291
4. Block ML, Zecca L, Hong J-S. Microglia-mediated neurotoxicity: Uncovering the molecular mechanisms. Nat Rev Neurosci 2007; 8: 57-69
5. Biber K, Neumann H, Inoue K, Boddeke HWGM. Neuronal on and off signals control microglia. Trends Neurosci 2007; 30: 596-602
6. Harms AS, Barnum CJ, Ruhn KA, Varghese S, Trevin'o I, Blesch A et al. Delayed dominant-negative tnf gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of Parkinson's disease. Mol Ther 2011; 19: 46-52
7. McCoy MK, Martinez TN, Ruhn KA, Szymkowski DE, Smith CG, Botterman BR et al. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. J Neurosci 2006; 26: 9365-9375
8. Zhang F, Qian L, Flood PM, Shi JS, Hong JS, Gao HM. Inhibition of IkB kinase-b protects dopamine neurons against lipopolysaccharide-induced neurotoxicity. J Pharmacol Exp Ther 2010; 333: 822-833
9. Block ML, Hong JS. Chronic microglial activation and progressive dopaminergic neurotoxicity. Biochem Soc Trans 2007; 35: 1127-1132
10. Kim YS, Choi DH, Block ML, Lorenzl S, Yang L, Kim YJ et al. A pivotal role of matrix metalloproteinase-3 activity in dopaminergic neuronal degeneration via microglial activation. FASEB J 2007; 21: 179-187
11. Meredith G, Sonsalla P, Chesselet M-F. Animal models of Parkinson's disease progression. Acta Neuropathol 2008; 115: 385-398
12. Chavkin C, James I, Goldstein A. Dynorphin is a specific endogenous ligand of the kappa opioid receptor. Science 1982; 215: 413-415
13. DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK. Beta-Arrestins and cell signaling. Ann Rev Physiol 2007; 69: 483-510
14. Bruijnzeel AW. Kappa-opioid receptor signaling and brain reward function. Brain Res Rev 2009; 62: 127-146
15. Ikeda K, Yoshikawa S, Kurokawa T, Yuzawa N, Nakao K, Mochizuki H. TRK-820, a selective kappa opioid receptor agonist, could effectively ameliorate L-DOPA-induced dyskinesia symptoms in a rat model of Parkinson's disease. Eur J Pharmacol 2009; 620: 42-48
16. Manzanares J, Lookingland KJ, Moore KE. Kappa opioid receptor-mediated regulation of dopaminergic neurons in the rat brain. J Pharmacol Exp Ther 1991; 256: 500-505
17. Margolis EB, Hjelmstad GO, Bonci A, Fields HL. k-Opioid agonists directly inhibit midbrain dopaminergic neurons. J Neurosc 2003; 23: 9981-9986
18. Waters CM, Peck R, Rossor M, Reynolds GP, Hunt SP. Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson's disease and Huntington's chorea. Neuroscience 1988; 25: 419-438
19. Carta A, Fenu S, Morelli M. Alterations in GAD67, dynorphin and enkephalin mRNA in striatal output neurons following priming in the 6-OHDA model of Parkinson's disease. Neurol Sci 2001; 22: 59-60
20. Wang Q, Shin EJ, Nguyen XK, Li Q, Bach JH, Bing G et al. Endogenous dynorphin protects against neurotoxin-elicited nigrostriatal dopaminergic neuron damage and motor deficits in mice. J Neuroinflammation 2012; 9: 124
21. Bidlack JM. Detection and function of opioid receptors on cells from the immune system. Clin Diagn Lab Immunol 2000; 7: 719-723
22. Alicea C, Belkowski SM, Sliker JK, Zhu J, Liu-Chen LY, Eisenstein TK et al. Characterization of kappa-opioid receptor transcripts expressed by T cells and macrophages. J Neuroimmunol 1998; 91: 55-62
23. Alicea C, Belkowski S, Eisenstein TK, Adler MW, Rogers TJ. Inhibition of primary murine macrophage cytokine production in vitro following treatment with the K-opioid agonist U50, 488H. J Neuroimmunol 1996; 64: 83-90
24. Belkowski SM, Alicea C, Eisenstein TK, Adler MW, Rogers TJ. Inhibition of interleukin-1 and tumor necrosis factor-Alpha synthesis following treatment of macrophages with the kappa opioid agonist U50, 488H. J Pharmacol Exp Ther 1995; 273: 1491-1496
25. Chao CC, Gekker G, Hu S, Sheng WS, Shark KB, Bu DF et al. kappa opioid receptors in human microglia downregulate human immunodeficiency virus 1 expression. Proc Natl Acad Sci 1996; 93: 8051-8056
26. Chao CC, Hu S, Gekker G, Lokensgard JR, Heyes MP, Peterson PK. U50,488 protection against HIV-1-related neurotoxicity: Involvement of quinolinic acid suppression. Neuropharmacology 2000; 39: 150-160
27. Hu S, Peterson PK, Chao CC. k-Opioid modulation of human microglial cell superoxide anion generation. Biochem Pharmacol 1998; 56: 285-288
28. Wee S, Koob GF. The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse. Psychopharmacology 2010; 210: 121-135
29. Saijo K, Winner B, Carson CT, Collier JG, Boyer L, Rosenfeld MG et al. A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammationinduced death. Cell 2009; 137: 47-59
30. Bhaskar K, Konerth M, Kokiko-Cochran ON, Cardona A, Ransohoff RM, Lamb BT. Regulation of tau pathology by the microglial fractalkine receptor. Neuron 2010; 68: 19-31
31. Luttrell LM, Lefkowitz RJ. The role of beta-Arrestins in the termination and transduction of G-protein-coupled receptor signals. J Cell Sci 2002; 115: 455-465
32. Zheng H, Loh HH, Law PY. Beta-Arrestin-dependent mu-opioid receptor-Activated extracellular signal-regulated kinases (ERKs) Translocate to nucleus in contrast to G protein-dependent ERK activation. Mol Pharmacol 2008; 73: 178-190
33. Loniewski K, Shi Y, Pestka J, Parameswaran N. Toll-like receptors differentially regulate GPCR kinases and arrestins in primary macrophages. Mol Immunol 2008; 45: 2312-2322
34. Fan H, Luttrell LM, Tempel GE, Senn JJ, Halushka PV, Cook JA. Beta-Arrestins 1 and 2 differentially regulate LPS-induced signaling and pro-inflammatory gene expression. Mol Immunol 2007; 44: 3092-3099
35. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011; 34: 637-650
36. Kawai T, Akira S. TLR signaling. Cell Death Differ 2006; 13: 816-825
37. Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: A target for neuroprotection? Lancet Neurol 2009; 8: 382-397
38. Gao HM, Liu B, Zhang W, Hong JS. Novel anti-inflammatory therapy for Parkinson's disease. Trends Pharmacol Sci 2003; 24: 395-401
39. Lawson LJ, Perry VH, Dri P, Gordon S. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 1990; 39: 151-170
40. Lee J-K, Chung J, McAlpine FE, Tansey MG. Regulator of G-protein signaling-10 negatively regulates NF-kB in microglia and neuroprotects dopaminergic neurons in Hemiparkinsonian rats. J Neurosci 2011; 31: 11879-11888
41. Kim WG, Mohney RP, Wilson B, Jeohn GH, Liu B, Hong JS. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: Role of microglia. J Neurosci 2000; 20: 6309-6316
42. Meredith GE, Sonsalla PK, Chesselet MF. Animal models of Parkinson's disease progression. Acta Neuropathol 2008; 115: 385-398
43. Flaisher-Grinberg S, Persaud SD, Loh HH, Wei LN. Stress-induced epigenetic regulation of kappa-opioid receptor gene involves transcription factor c-Myc. Proc Natl Acad Sci USA 2012; 109: 9167-9172
44. Bruijnzeel AW. Kappa-opioid receptor signaling and brain reward function. Brain Res Rev 2009; 62: 127-146
45. Gao H, Sun Y, Wu Y, Luan B, Wang Y, Qu B et al. Identification of beta-Arrestin2 as a G protein-coupled receptor-stimulated regulator of NF-kappaB pathways. Mol Cell 2004; 14: 303-317
46. Qian L, Wu HM, Chen SH, Zhang D, Ali SF, Peterson L et al. beta2-Adrenergic receptor activation prevents rodent dopaminergic neurotoxicity by inhibiting microglia via a novel signaling pathway. J Immunol 2011; 186: 4443-4454
47. Simonin F, Valverde O, Smadja C, Slowe S, Kitchen I, Dierich A et al. Disruption of the [kappa]-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective [kappa]-Agonist U-50,488H and attenuates morphine withdrawal. EMBO J 1998; 17: 886-897
48. Paxinos G, Franklin KBJ. The Mouse Brain In Stereotaxic Coordinates. 2nd edn, Elsevier Academic Press: Amsterdam; Boston, 2004
49. Fath T, Ke YD, Gunning P, Gotz J, Ittner LM. Primary support cultures of hippocampal and substantia nigra neurons. Nat Protoc 2009; 4: 78-85
50. Saura J, Tusell JM, Serratosa J. High-yield isolation of murine microglia by mild trypsinization. Glia 2003; 44: 183-189
51. Ho PC, Tsui YC, Feng X, Greaves DR, Wei LN. NF-kappaB-mediated degradation of the coactivator RIP140 regulates inflammatory responses and contributes to endotoxin tolerance. Nat Immunol 2012; 13: 379-386
52. Leong ML, Gu M, Speltz-Paiz R, Stahura EI, Mottey N, Steer CJ et al. Neuronal loss in the rostral ventromedial medulla in a rat model of neuropathic pain. J Neurosci 2011; 31: 17028-17039
53. Howard CV, Reed MG. Unbiased Stereology: Three-Dimensional Measurement In Microscopy. BIOS Scientific: Oxford, UK, 1998